Lipid panel monitoring should occur at 8-12 weeks after GLP-1 initiation and periodically thereafter
These ranges are research planning, not personal dosing recommendations, and no published human Phase 2 or Phase 3 dose-finding trial exists
Common adverse effects include: Gastrointestinal symptoms nausea, vomiting, diarrhoea, constipation, and abdominal pain (affecting up to 40% of users) Reduced appetite and weight loss Injection site reactions redness, itching, or discomfort Hypoglycaemia particularly when used alongside insulin or sulfonylureas More serious but rare adverse effects include pancreatitis (inflammation of the pancreas) and gallbladder disease
CagriSema dosing protocols are being studied in clinical trials showing even greater weight loss potential
GLP-2 Medications: Gut Health and Metabolic Support GLP-2 primarily supports intestinal health rather than solely suppressing appetite
One strategy is to lower the dosage of glutathione taken or administered
